Here’s what you should know:
1. Analysts believe Allergan will announce fourth quarter 2017 earnings of $0.83 per share Feb. 14, as well.
2. Analysts believe the company’s full-year earnings will increase approximately 13.98 percent, year over year.
3. Based on the projected earnings, 18 analysts awarded Allergan a “buy” rating and eight have deemed it a “hold.” No analysts issued a “sell” rating.
More articles on supply chain:
Healthcare-related lobbying hits $555M in 2017 — 6 statistics on lobbying in healthcare
Advanced Medical Group joins National Spine & Pain Centers — 4 things to know
Preoperative opioid users more likely to abuse opioids after TKA — 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
